In latest setback, AstraZeneca’s high hopes for its lupus drug anifrolumab crushed by a PhIII failure
The last of the late-stage autoimmune drugs still left at AstraZeneca just went down to a stinging defeat in Phase III.
The pharma giant didn’t waste any time with its statement. Their drug anifrolumab — which they once held high hope of success for — failed the primary endpoint for lupus: significantly reducing disease activity for patients with systemic lupus erythematosus.
This is the first of two Phase III studies for this antibody, which targets type I interferons including IFN-α, IFN-β and IFN-ω. But with the first big, 52-week trial a flop, the whole program — including two other mid-stage trials — have just come under a very dark cloud.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
